BIOVECTRA ANNOUNCES $5M INVESTMENT IN START OF NEW MANUFACTURING PROJECT
BIOVECTRA ANNOUNCES $5M INVESTMENT IN START OF NEW MANUFACTURING PROJECT
 
Charlottetown, PE - September 14, 2012 - BioVectra is announcing today that a new, $5M construction project has begun, in conjunction with an international pharmaceutical development partner.
The large-scale manufacturing operation, to be located inside a dedicated wing of its existing cGMP facility at 11 Aviation Avenue, will be constructed, commissioned, and qualified, over the next 6 month period.  The new capacity will provide its client with active pharmaceutical ingredient for the client’s launch preparation requirements.
Upon completion, the new manufacturing expansion will employ 35 new employees, in manufacturing, engineering, and technical support functions.
Noted Ron Keefe, CEO of BioVectra, “We are pleased to announce the latest expansion project by our company which has resulted from our ability to support the needs of this customer through their clinical development of this product.  We continue to excel at forging long-term relationships with our clients, and they see the opportunity to utilize our proven skills in project management to serve their business needs.”
Over the 2011-2013 period, BioVectra has or will invest $50 Million to expand its facilities and technical capabilities in Charlottetown, in response to its rapid growth as a biopharmaceutical industry partner.  “While contract manufacturing is a highly competitive, cost-driven business, BioVectra has hit its stride in being a strategic partner to our clients,” stated Dale Zajicek, President of BioVectra.
About BioVectra Inc.
BioVectra is a supplier to the global pharmaceutical industry, operating from three, FDA inspected facilities in Prince Edward Island, Canada.  The company is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules.  BioVectra has submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada.  These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product.


For more information, please contact:

Heather Delage
Director, Sales & Marketing
hdelage@biovectra.com

(866) 883-2872 / (902) 566-9116

info@biovectra.com
www.biovectra com

View PDF